Lymphoma Regression Induced by Monoclonal Anti-Idiotypic Antibodies Correlates With Their Ability to Induce Ig Signal Transduction and Is Not Prevented by Tumor Expression of High Levels of Bcl-2 Protein
作者： WM Vuist , R Levy , DG Maloney
DOI: 10.1182/BLOOD.V83.4.899.899
关键词:
摘要: Custom-made monoclonal anti-idiotype antibodies (anti-Id MoAbs) have been tested as a treatment modality in 34 non-Hodgkin9s lymphoma (NHL) patients. Partial or complete tumor remissions induced with this 68% of these One mechanism by which anti- idiotype may responses is via direct antiproliferative effect on the cells, resulting apoptosis. Primary NHL cells do not proliferate well enough vitro to test hypothesis directly. Therefore, we studied signal transduction through surface Ig receptor measured induction cellular protein tyrosine phosphorylation. To assess whether bcl-2 could protect from death anti-Id MoAb, also level same cells. We found strong correlation between ability an MoAb induce increase phosphorylation and its regression patient. By contrast, expressed was correlated clinical response treatment.
ashpublications.org
bloodjournal.org参考文章(42)
SL Brown, RA Miller, SJ Horning, D Czerwinski, SM Hart, R McElderry, T Basham, RA Warnke, TC Merigan, R Levy, Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood. ,vol. 73, pp. 651- 661 ,(1989) , 10.1182/BLOOD.V73.3.651.651
RA Miller, R Levy, DG Maloney, S Brown, DK Czerwinski, TM Liles, SM Hart, Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells Blood. ,vol. 80, pp. 1502- 1510 ,(1992) , 10.1182/BLOOD.V80.6.1502.1502
Eduardo Cuende, Jose Enrique Alés‐Martínez, Liyun Ding, M Gonzalez‐Garcia, C Martinez, G Nunez, None, Programmed cell death by bcl-2-dependent and independent mechanisms in B lymphoma cells. The EMBO Journal. ,vol. 12, pp. 1555- 1560 ,(1993) , 10.1002/J.1460-2075.1993.TB05799.X
JN Lowder, TC Meeker, M Campbell, CF Garcia, J Gralow, RA Miller, R Warnke, R Levy, Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses. Blood. ,vol. 69, pp. 199- 210 ,(1987) , 10.1182/BLOOD.V69.1.199.199
C. J. M. Melief, F. v. Buitenen, A. Hekman, W. M. J. Vuist, P. Rümke, M. A. de Rie, Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model. Cancer Research. ,vol. 49, pp. 3783- 3788 ,(1989)
I D Bernstein, C C Badger, E Y Denkers, J A Ledbetter, Influence of antibody isotype on passive serotherapy of lymphoma. Journal of Immunology. ,vol. 135, pp. 2183- 2186 ,(1985)
D. Hockenbery, M. I. Walton, P. M. O'Connor, K. W. Kohn, D. Whysong, S. J. Korsmeyer, Constitutive Expression of Human Bcl-2 Modulates Nitrogen Mustard and Camptothecin Induced Apoptosis Cancer Research. ,vol. 53, pp. 1853- 1861 ,(1993)
D. Hata, K. Katamura, H. Mikawa, T. Ishigami, M. Mayumi, Kwang-Myong Kim, Y. Higaki, Y. Horiguchi, T. Heike, Anti-IgM antibody-induced cell death in a human B lymphoma cell line, B104, represents a novel programmed cell death. Journal of Immunology. ,vol. 148, pp. 360- 368 ,(1992)
M. Seto, U. Jaeger, R. D. Hockett, W. Graninger, S. Bennett, P. Goldman, S. J. Korsmeyer, Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. The EMBO Journal. ,vol. 7, pp. 123- 131 ,(1988) , 10.1002/J.1460-2075.1988.TB02791.X
C J Melief, A Hekman, W M Vuist, F van Buitenen, Two Distinct Mechanisms of Antitumor Activity Mediated by the Combination of Interleukin 2 and Monoclonal Antibodies Cancer Research. ,vol. 50, pp. 5767- 5772 ,(1990)